# Efficacy of Gemtuzumab Ozogamycin for Patients Presenting an Acute Myeloid Leukemia (AML) With Intermediate Risk

> **NCT00860639** · PHASE3 · COMPLETED · sponsor: **Nantes University Hospital** · enrollment: 327 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** gemtuzumab ozogamycin

## Key facts

- **NCT ID:** NCT00860639
- **Lead sponsor:** Nantes University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2016-09-26
- **Final completion:** 2016-09-26
- **Target enrollment:** 327 (ACTUAL)
- **Last updated:** 2017-01-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00860639

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00860639, "Efficacy of Gemtuzumab Ozogamycin for Patients Presenting an Acute Myeloid Leukemia (AML) With Intermediate Risk". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00860639. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*